Evotec AG and Eternygen GmbH have entered a drug discovery collaboration to develop small molecule inhibitors against an Eternygen target to treat metabolic diseases using Evotec's technology platform. Eternygen is developing the novel target, sodium coupled citrate transporter NaCT, a key regulator of energy metabolism involved in diabetes and obesity. Evotec will use its drug discovery platform to discover and develop a suitable clinical candidate.
Marco Janezic, chief executive officer of Eternygen GmbH, said, "Evotec as a world-leading provider for drug discovery and development services and its deep expertise in the area of metabolic diseases is the optimal partner for
Eternygen as a project focused company to drive the development process as fast as possible until proof of concept."
Dr. Mario Polywka, chief operating officer of Evotec, said, "We are pleased to enter this collaboration with Eternygen and we are confident that the combination of Eternygen's and our expertise in metabolic drug discovery and development will lead to success."